TOPページ
|
英語
日本語
|
CONNECT WITH US:
ホーム
JCNについて
サービス
お問い合わせ
会員企業ログイン
*
ホーム
プレスリリース一覧
China Medical System Holdings Ltd.
プレスリリース一覧
China Medical System (00867) Obtained Class 1 Innovative Drug Long-acting Anti-IL-4Ra Monoclonal Antibody MG-K10
Jan 24, 2025 23:00 JST
More info..
China Medical System (00867) Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer's Type
Jan 09, 2025 09:00 JST
China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 8 January 2025, the Group through a wholly-owned subsidiary of the Company entered into a License, Collaboration and Distribution Agreement (the "Agreement") with Alpha Cognition Inc. ("Alpha") of the improved new drug ZUNVEYL (benzgalantamine delayed-release tablets)("ZUNVEY" or the "Product") for the treatment of mild-to-moderate dementia of the Alzheimer's type.
More info..
China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China
Dec 09, 2024 14:00 JST
China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China
More info..
China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia
Dec 02, 2024 22:30 JST
China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia
More info..
China Medical System: New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China
Sep 24, 2024 22:00 JST
China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on September 24, 2024, the New Drug Application (NDA) for vitiligo indication of ruxolitinib phosphate cream (the "ruxolitinib cream" or the "Product") has been accepted by the National Medical Products Administration of China (NMPA).
More info..
China Medical System (00867) Released its 2024 Interim Results: Steady Increase in Revenue and Profit Compared with 2H 2023
Aug 16, 2024 14:00 JST
On August 15, 2024, China Medical System Holdings Limited ("CMS" or the "Company") released its 2024 interim results announcement, with a steady increase in overall revenue and profit for the period compared to the second half (2H) of 2023. In the first half (1H) of 2024, the Company recorded a turnover of RMB3,611.1 million, representing a decrease of 21.7% compared with 1H 2023, an increase of 6.1% compared with 2H 2023.
More info..
China Medical System: NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China
Aug 05, 2024 23:00 JST
China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 30 July 2024, the New Drug Application (NDA) for an additional indication of Methotrexate Injection (the "Product") has been approved by the National Medical Products Administration of China (NMPA).
More info..
China Medical System (867.HK) Reincluded in S&P Global Sustainability Yearbook (China Edition) and Maintained MSCI ESG "AA" Rating
Jul 16, 2024 21:00 JST
In July 2024, China Medical System Holdings Limited ("CMS" or the "Group") has once again been recognized for its outstanding performance and continuous progress in sustainable development.
More info..
China Medical System Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China
Jun 25, 2024 21:46 JST
On June 25, China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") announced the completion of dosing for the first subject in the phase III bridging trial of ruxolitinib cream (the "Product") in atopic dermatitis ("AD") in China.
More info..
China Medical System: Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets Approved for Marketing in China
Jun 18, 2024 19:53 JST
More info..
China Medical System: New Drug Application of Desidustat Tablets Accepted in China
Apr 23, 2024 23:06 JST
More info..
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
Apr 01, 2024 21:30 JST
More info..
China Medical System (867.HK) 2023 Annual Results: Despite of the Temporary Financial Performance Pressure, Fresh Catalysts Emerged from Successive Innovation Breakthroughs
Mar 28, 2024 11:29 JST
More info..
China Medical System (00867) Obtained Exclusive License of a First-line Phosphate-lowering Drug Velphoro(R)
Feb 04, 2024 10:00 JST
More info..
CMS(00867) Joins Hands with Pharmaron to Promote the Singapore Manufacturing Plant Acquisition and CDMO Business in SEA
Jan 02, 2024 15:00 JST
More info..
China Medical System: 4 Products Have Been Newly Included or Continued to be Included in the NRDL
Dec 13, 2023 18:36 JST
More info..
China Medical System Gained Exclusive License of an Anti-Ischemic Stroke Class 1 Innovative Drug
Aug 24, 2023 21:00 JST
More info..
China Medical System Once Again Received MSCI-ESG 'AA' Rating, Leading the Industry in ESG Management
Jul 31, 2023 21:00 JST
Recently, MSCI (Morgan Stanley Capital International), the world's largest index company, announced the latest Environmental, Social, and Governance (ESG) evaluation report for China Medical System Holdings limited ("CMS" or the "Group"), who achieved an "AA" rating and surpassed 75% of global peers with leading ESG management practices.
More info..
China Medical System: The first 'Diazepam Nasal Spray' Approved for Marketing in China
Jun 12, 2023 21:00 JST
More info..
China Medical System: An Innovative Drug, ILUMETRI 'Tildrakizumab Injection' Approved for Marketing in China
May 30, 2023 23:00 JST
On May 30, China Medical System Holdings Limited ("CMS" or the "Group") announced that on 26 May 2023, the New Drug Application (NDA) of Tildrakizumab Injection under the brand name of ILUMETRI has been approved by the National Medical Products Administration of China (NMPA). ILUMETRI is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
More info..
CMS Releases Its 2022 Interim Report, Achieves Sustained Growth with Its Platform Strategy
Aug 26, 2022 19:00 JST
More info..
1
新着プレスリリース
三菱造船、アンモニアを燃料とする大型アンモニア輸送船の設計基本承認(AiP)を船級協会から取得
2025年03月14日 14時15分
富士通、「第57回(令和6年度)市村賞 市村産業賞」の「貢献賞」を受賞
2025年03月14日 12時50分
Habitat for Humanity offers up to US$40,000 in grants for innovative youth-led housing solutions in Asia-Pacific
2025年03月14日 10時18分
TreasureNFT Introduces New Features to Enhance NFT Trading Efficiency
2025年03月14日 09時00分
Hong Kong delegation concludes IRES mission in Bangkok
2025年03月13日 16時41分
CleverTap partners with upGrad to build a Deep Learning Track to upskill Marketers with Hands-On AI & Analytics Training
2025年03月13日 16時00分
Honda、第4回日経統合報告書アワード優秀賞を初受賞
2025年03月13日 14時15分
TOYOTA、新型クラウン(エステート)を発売
2025年03月13日 14時10分
MarketingPulse and eTailingPulse return on 19 March
2025年03月12日 17時05分
三菱重工マリタイムシステムズ、海上保安庁向け大型巡視船の命名・進水式を実施
2025年03月12日 15時00分
MHIET、6気筒500kWクラスの水素エンジン発電セットで定格出力を達成
2025年03月12日 14時15分
商船三井と富士通、船員配乗計画にAIシステムを活用
2025年03月12日 14時15分
富士通、Sustainalytics のESG Risk Ratingsで「Industry Top Rated」と「Region Top Rated」に選出
2025年03月11日 10時15分
PerfectSwell(R)のテストがサンパウロサーフクラブで開始
2025年03月11日 08時00分
アリマンタシォン・クシュタール、セブン&アイに対する買収提案について現状説明
2025年03月11日 08時00分
富士通、9年連続で「健康経営優良法人~ホワイト500~」に認定
2025年03月10日 16時20分
エーザイ、「健康経営銘柄2025」に初選定
2025年03月10日 15時45分
Hola Prime to Introduce Prime Academy for Personalized Trader Mentorship
2025年03月10日 13時00分
マツダ、「AUTOMOBILE COUNCIL 2025」に出展
2025年03月10日 12時00分
Honda、大型クルーザーモデル「Rebel 1100」シリーズの一部仕様を変更するとともに、「Rebel 1100 S Edition Dual Clutch Transmission」をタイプ追加し発売
2025年03月07日 11時30分
もっと見る >>